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Edited by Robert BaroukiAbstract The recent identiﬁcation of hypoxia-inducible-factor
(HIF) prolyl hydroxylases (PHD1, 2, and 3), which modify HIF-
1a in an oxygen-dependent manner, provided an important link
between oxygen availability and hypoxia-induced gene expres-
sion. However, little is known about the regulation of the PHDs.
To investigate the transcriptional regulation of PHD1, we cloned
the PHD1 gene promoter. Here, we report that the expression of
PHD1 is reduced under hypoxic conditions. Furthermore, we
identiﬁed binding sites for aryl hydrocarbon nuclear translocator
(ARNT/HIF-1b) within the PHD1 promoter, and showed that
ARNT is associated in vivo with the PHD1 promoter following
hypoxia, which implies a role for ARNT in the hypoxia-
dependent regulation of PHD1. Taken together, our ﬁndings
suggest a hypoxia-induced regulatory loop of PHD1 expression,
mediated by ARNT.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Maintainingoxygenhomeostasis is essential for the survival of
all organisms, and the ability of cells to sense and respond to
changes in oxygen availability is critical for many physiological
and pathological processes. Conserved oxygen responsive path-
waysarepresent inmostmammaliancells andresult inchanges in
gene expression [1]. The hypoxia-inducible-factor-1 (HIF-1) is a
central transcription factor complexdriving the cellular response
to lack of oxygen. Following induction by hypoxia, HIF-1 binds
toahypoxia responsive element (HRE)within thepromotersofa
rapidly increasing number of target genes and drives the cellular
adaptive response to reduced oxygen availability. HIF target
genes mediate changes in cellular metabolism such as increased
glucose uptake and glycolysis, red blood cell maturation, the
productionof several angiogenic factorsand their receptors [2,3],
and, under severe hypoxia, apoptosis [4,5].
HIF-1 is a heterodimeric complex consisting of two subunits:
HIF-1b (also termed ARNT: aryl hydrocarbon nuclear trans-
locator),which is expressed constitutively in the nucleus andalso
participates in other transcriptional pathways, and HIF-1a,
whose stable expression is tightly regulated in a hypoxia-
dependentmanner. In normoxia, HIF-1a is rapidly degraded by* Corresponding author. Fax: +972-08-9465265.
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allow heterodimer formation and transcriptional activation
[6,7]. When hypoxia occurs, this degradation is suppressed and
HIF-1a is rapidly stabilized. The degradation of HIF-1a is
mediated by the product of the Von Hippel-Lindau (VHL) tu-
mor suppressor gene, which acts as the recognition component
of a ubiquitin E3 ligase complex. VHL interacts speciﬁcally with
an oxygen-dependent degradation domain (ODDD) within
HIF-1a. VHL recognition requires enzymatic hydroxylation of
speciﬁc prolyl residues within the HIF-1a ODDD, which de-
pends on the availability of molecular oxygen (reviewed in [8]).
The recent cloning of the mammalian HIF prolyl hydroxylases
provided an important link between oxygen availability and
HIF-1a activation, since the activity of the PHDs was shown to
depend on oxygen [9–11]. The three prolyl hydroxylases were
termed PHDs,HPHs orEGLNs by various groups, andwe shall
hereafter use the PHD nomenclature. We cloned the mouse
homolog of PHD1, mPHD1 [12], which we initially designated
Falkor [13].
Under normoxic conditions, mPHD1 is expressed in all the
tissues we examined, most abundantly in testis [13]. The other
PHDs were also shown to be ubiquitously expressed [9,14]. The
concomitant expression of all three PHDs raises the possibility
that they might have distinctive roles. Indeed, PHD2 was sug-
gested recently to be the key oxygen sensor of the three family
members [15]. Additionally, it was shown that when cells are
exposed to hypoxic conditions, or to hypoxia mimetic drugs,
there is an increase inmRNA levels of PHD2andPHD3, but not
of PHD1 [9,14,16]. Thus, the PHDs seem to also diﬀer in their
regulation.
In this study, we set out to learn about the transcriptional
regulation of PHD1. We cloned the human PHD1 gene pro-
moter and found putative binding sites for several transcription
factors that might participate in its regulation. We show here
that the mRNA levels of PHD1 decrease in response to the hy-
poxia-mimetic drug desferrioxamine (DFO) or to hypoxia,
suggesting hypoxia-dependent regulation of PHD1. Further-
more, we found that HIF-1b (ARNT) is associated in vivo with
the PHD1 gene promoter following hypoxia, which implies a
role for ARNT in the hypoxia-dependent regulation of PHD1.2. Materials and methods
2.1. Cloning of the PHD1 genomic 50 region
Genomic DNA was prepared from primary human smooth muscle
cells and the 50 ﬂanking region of the PHD1 gene was ampliﬁed using
the primers: Forward: 50-CTTTTCTCAAGGGCAACCCGCAC-30ation of European Biochemical Societies.
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uct was cloned using the pcDNA3.1/V5-His-TOPO TA expression kit
(Invitrogen). PHD1promoter-luc reporter plasmid was constructed by
subcloning the PHD1 promoter into the pGL3-Basic luciferase plas-
mid (Promega).
2.2. Transient transfection and luciferase assay
Cells were seeded in 24-well culture dishes. Triplicate wells were
transfected with 50 ng of a reporter plasmid expressing the ﬁreﬂy lu-
ciferase gene under the transcriptional control of the PHD1 gene
promoter, together with a control b-gal plasmid. DFO was added 24 h
post-transfection and luciferase activity was assayed 48 h post-trans-
fection. Luciferase assays were performed using (D)-luciferin (Roche).
Luminescence was determined using a Rosys-Anthos Lucy 3 lumi-
nometer. The luciferase values were normalized to b-gal activity.
2.3. Chromatin immunoprecipitation (ChIP) analysis
ChIP experiments were performed according to the Farenham labo-
ratoryprotocol [17].HCT116 cells, either non-treated or treatedwith 200
lMDFO for 6 h, were ﬁxed by adding Formaldehyde (Merck), in a ﬁnal
concentration of 1% at room temperature for 10 min. Fixation was
stopped by the addition of glycine to a ﬁnal concentration of 0.125 M.
Plates containing HCT116 cells were rinsed with cold PBS, incubated
with 5ml of 20% trypsin–EDTAand then scraped oﬀ plates. Nuclei were
collected by suspending the cells for 20 min in cell lysis buﬀer and mi-
crocentrifugation at 4000 rpm. The nuclei were resuspended in nuclei
lysis buﬀer. Samples were sonicated on ice to an average length of 600–
1000 bp and thenmicrofuged at 14 000 rpm. The chromatin solutionwas
preclearedwith the addition of proteinAbeads (blockedwithBSA) for 2
h at 4 C. Precleared chromatin from 50 106 cells was diluted 1:5 in
dilution buﬀer and incubated with 2 lg of anti-ARNT antibody (Alexis
Biochemicals), or anti-HA antibody (Santa-Cruz Biotechnology) for 12
h. 30 ll Agarose beads coated with anti-mouse antibody (Amersham)
was added for two additional hours. Immunoprecipitants were washed
twicewith dilutionbuﬀer, twicewithwashbuﬀer andoncewithTEbuﬀer
(composition of buﬀers is detailed in [17]). Crosslinks were reversed by
addition ofNaCl to a ﬁnal concentration of 200mM, proteins andRNA
were removed by addition of 10 lg of RNase A per sample for 30 min
followed by addition of 30 lg proteinase K for 2 h at 42 C. Cross-links
were reversed by incubation at 65 C overnight. DNA was extracted
usingQiagenPCRextraction kit. 5%of total input sampleswas collected
bymicrocentrifugation. Immunoprecipitated samples were resuspended
in 50ll ofH2O, input sampleswere resuspended in 50ll ofH2Oand then
diluted 1:10. All samples were analyzed by PCR. PCRs contained 2 ll of
immunoprecipitated or diluted total input, 50 ng of each primer, 10%
DMSO and ReadyMix PCRmaster mix (Promega) in a total volume of
50 ll. After 35 cycles of ampliﬁcation, PCR products were run on a 2%
agarose gel and analyzed by ethidium bromide staining.
Primers used are:
semi-quantitative PCR: ARNT1+2 sites:
Forward: 50-GTAGGCCACGGACCGCTGTTTCC-30
Reverse: 50-CGGCGCCGCCGTTTGTGCC-30
ARNT3 site: Forward: 50-GTGCCCTGGATGGGGGCACC-30
Reverse: 50-CTGCCTCGGCGTTCCAGAAAG-30
Real-time PCR: ARNT1+2 sites:
Forward: 50-GCCATTTCTCCGTCTCTCACC-30
Reverse: 50-TCAGCTCCTCCTCCTTCTCG-30
ARNT3 site: Forward: 50-GGCACCTTTATCTCTCGTCCTGT-30
Reverse: 50-CAGAGGAAAGGACGGAGGAG-30Fig. 1. Nucleotide sequence of the 50-ﬂanking region of the human
PHD1 gene. The various potential transcriptional factor binding sites
are indicated. The nucleotide number was counted from the ﬁrst base
of the initiation codon.3. Results and discussion
3.1. Cloning of human genomic DNA fragment containing the
PHD1 promoter
To facilitate studies on transcriptional regulation of PHD1,
we cloned a genomic DNA fragment containing the human
PHD1 promoter. The promoter containing region from the 50
ﬂanking sequence of human PHD1 was predicted by using the
PromoterInspector software at the Genomatix site (http://
www.genomatix.de). Primers designed according to the soft-
ware’s prediction were used to obtain a 2 kb fragment up-stream of the PHD1 gene from genomic DNA prepared from
human primary smooth muscle cells.
The PCR product was puriﬁed, cloned as described in Sec-
tion 2 and sequenced. The nucleotide sequence of the PHD1
promoter region is shown in Fig. 1.
3.2. Sequence analysis of the human PHD1 promoter
To ﬁnd out if the promoter contains potential regulatory
elements, we used the web-based program MatInspector
(http://www.gsf.de/biodv/matinspector.html). This program
predicts putative binding sites for transcription factors within a
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known transcription factors which might transcriptionally
regulate the expression of PHD1 such as SP1, GATA-1, NF-
jB, and N-Myc. Their putative binding sites are indicated in
Fig. 1. Additionally, the results of the analysis of the PHD1
promoter sequence predicted three binding sites for HIF-1b/
ARNT.
3.3. Promoter activity and hypoxia-dependent regulation of
PHD1 expression
The 2 kb PCR product containing the 50 genomic region of
the human PHD1 gene was cloned into the luciferase reporter
plasmid pGL3-basic.
To test for transcriptional activity of the putative promoter,
HCT116 cells were transfected with the putative PHD1 pro-
moter in pGL3-basic or with the empty vector. 48 h following
transfection, cells were harvested and luciferase activity driven
by the PHD1 promoter was measured. As seen in Fig. 2A,
there was a dose-dependent, strong transcriptional activity
from the plasmid containing the cloned genomic region, con-
ﬁrming that it includes the promoter of PHD1. To test whether
the expression of PHD1 is aﬀected by hypoxia, HCT116 cells
were transfected as in Fig. 2A, treated with the hypoxia mi-
metic drug DFO 24 h following transfection, and then ana-
lyzed for luciferase activity. Fig. 2B shows that the hypoxicFig. 2. Transcription activity and response to DFO of the PHD1
promoter. (A) Luciferase assay in HCT116 cells transfected with either
50 ng pGL3-basic or with increasing amounts of the PHD1 promoter
cloned into pGL3-basic as indicated. Cells were plated at 3 105 cells/
well in a 24-well plate. Results shown are the average of triplicate wells
of a representative experiment, normalized to b-gal activity. (B) Lu-
ciferase assay as in (A). Cells were transfected with 50 ng PHD1
promoter-pGL3 basic and were left untreated or were treated over-
night with 200 lM DFO.conditions caused by DFO resulted in suppression of tran-
scription from the PHD1 promoter.
We next wanted to know whether this hypoxia-induced
suppression of PHD1 expression is evident in expression
analysis in cells. To that end, we performed a semi-quantitative
RT-PCR of both mouse (C2C12 skeletal myoblast cell line)
and human (HCT116) derived cells. We performed our ex-
periments in HCT116 cells, which are p53 deﬁcient, since we
previously showed that the expression and the activity of
mPHD1 are p53 independent [12,13]. Both cell lines showed a
decrease in PHD1 mRNA following treatment of cells with
DFO, starting from 16 h following treatment. PCR with
primers for the house keeping gene GPDH is shown as a
loading control (Fig. 3A). To conﬁrm this observation, we also
performed a Northern blot analysis on RNA prepared from
HCT116 cells treated with DFO, as compared to RNA pre-
pared from non-treated cells. Upon treatment with DFO,
a reduction in PHD1 mRNA levels was detected in cells. A
probe for GPDH was hybridized with the membrane as a
loading control (Fig. 3B).
This observation was further supported by a quantitative
real-time PCR analysis performed on cDNA from HCT116 or
from the breast carcinoma cell line MCF-7 cells treated with
DFO. The same experiment was performed with cDNA of
HCT116 cells incubated in 1% O2 hypoxia incubator. There
was about two folds reduction in PHD1 expression (Fig. 3C
and D). The results were normalized to those of GPDH or to
b-tubulin, as indicated, and show a representative experiment
out of four such experiments performed.
These ﬁndings suggested that there might be a regulatory
pathway in cells following hypoxic stress to downregulate
PHD1. However, it was recently suggested that PHD2, and
not PHD1 or PHD3, is the relevant hydroxylase controlling
HIF-1a levels in vivo; silencing of PHD2, but not of PHD1 or
PHD3 by siRNA was suﬃcient to stabilize and activate HIF-
1a in normoxia [15]. Interestingly, PHD3 and PHD1 were both
identiﬁed in contexts other than hypoxia and were suggested to
be cell growth regulators [13,18–20]. Thus, their regulation
may be connected to their other targets. The signiﬁcance of
PHD1 downregulation following hypoxia may become clearer
as more target proteins are identiﬁed.
3.4. Transcriptional regulation of PHD1 by ARNT
Hypoxic-dependent regulation of the prolyl hydroxylases
mRNA was recently suggested to depend on the HIF tran-
scription factor itself [15,16]. We were therefore most inter-
ested in the possible regulation of PHD1 by ARNT, as
implied by the ARNT binding site we found in the PHD1
promoter.
We next asked whether ARNT might be the transrepres-
sor responsible for the downregulation of PHD1 following
hypoxia. To conﬁrm binding of ARNT to its consensus sites
within the PHD1 promoter, we performed ChIP analysis,
as described in Section 2. HCT116 cells were treated with
DFO for 6 h or were left untreated. As seen in Fig. 4,
PHD1 promoter sequences containing the putative ARNT
consensus sites were selectively immunoprecipitated with
anti-ARNT antibodies following treatment with DFO.
Fragments immunoprecipitated with anti-HA tag antibodies
are shown as control for non-speciﬁc binding. Thus, ARNT
is associated in vivo with the PHD1 promoter under hypoxic
conditions.
Fig. 4. ARNT is associated in vivo with the PHD1 promoter. (A) PCR
analysis of ChIP products. The consensus sites for ARNT found at
)1944 and at )1439 were designated ARNT1 and ARNT2 sites, re-
spectively. These two sites are too closely located to be eﬃciently
separated by ChIP, and were thus analyzed together (ARNT 1+2 sites,
upper panel). The site found at )939 was designated ARNT3 site
(lower panel). nt: non-treated. (B) Real-time PCR analysis of ChIP
products. PCR was done in duplicates. Results are shown as % of
input, with error bars.
Fig. 3. Transcription of PHD1 is suppressed under hypoxia. (A) RT-
PCR of cDNA prepared from HCT116 cells. Cells were left non-
treated (nt) or were treated with 200 lM DFO overnight (left panel).
The right panel shows RT-PCR of cDNA from C2C12 cells for the
indicated time periods. PCR with GPDH primers is shown as loading
control. (B) Northern blot of RNA from HCT116 cells, either non-
treated (nt) or treated with 200 lM DFO overnight. RNA was probed
with PHD1 cDNA speciﬁc probe or with GPDH probe as loading
control. (C) cDNA from HCT116 or MCF-7 cells was prepared as in
(A) and analyzed by real-time PCR. The results shown are the average
of duplicate wells of a representative experiment, normalized to those
of GPDH (HCT116) or b-tubulin (MCF-7), with error bars. (D)
HCT116 cells were incubated overnight in a 1% O2 incubator, collected
and cDNA was analyzed by real-time PCR as in (C). The results were
normalized to those of b-tubulin.
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gene
The ubiquitously expressed basic helix-loop-helix (bHLH)-
PAS protein ARNT forms transcriptionally active heterodi-
mers with a variety of other bHLH-PAS proteins, including
HIF-1a and AHR (arylhydrocarbon receptor), as well as
ARNT homodimers. These complexes regulate gene expres-
sion in response to hypoxia and xenobiotics, respectively
[21,22]. Interestingly, ARNT was shown to heterodimerize
with the murine protein Single Minded (SIM), another mem-
ber of the bHLH-PAS family, and trans-repress HIF-1a tar-
gets under hypoxic conditions [23,24]. This suggests that
ARNT may be involved in both induction and repression of
genes under hypoxia, depending on its heterodimer partner.
Interestingly, the binding site for ARNT, found at )939
(ARNT3) in the PHD1 promoter (50-GTGCGTG-30), is typi-cal for heterodimers of ARNT with SIM and not to ARNT
homodimers or ARNT-HIF-1a heterodimers, which bind the
HRE [25]. Thus, ARNT may heterodimerize with SIM to re-
press PHD1 expression.
On the other hand, the binding site at )1439 (ARNT2) (50-
CACGTG-30) is the DNA recognition site speciﬁed for ARNT
homodimers and the binding site at )1944 (ARNT1) (50-
GCGTG-30) is an AHR/ARNT consensus site [26]. Further
experiments are needed to decipher the molecular mechanism
underlying the regulation of PHD1 by ARNT following hyp-
oxic stress, and to identify the relevant partners of ARNT in
this regulation.
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